Impact Analysis of Covid-19

The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Bacteriophage Therapy Market – Market Insights

Bacteriophages have been researched as a new alternative to antibiotics. In this therapy, the viruses are used to inject their genetic material into bacteria and use their host machinery to multiply themselves. This phage therapy is used to treat or to prevent bacterial infections in patients’ body.

Figure 1. Global Bacteriophage Therapy Market

Bacteriophages Therapy  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2020)

Rising adoption of inorganic growth strategies by market players is expected to drive growth of the bacteriophage therapy market

Bacteriophage therapy market is expected to witness significant growth owing to increasing merger and acquisition activities by market players to strengthen their pipeline of phage therapy candidates and also to enhance their research and development capabilities. For instance, in January 2019, Locus Biosciences Inc. entered into an exclusive collaboration and license agreement with Janssen Pharmaceuticals, Inc. (part of the Janssen Pharmaceutical Companies of Johnson & Johnson) to develop, manufacture, and commercialize CRISPR-Cas3-enhanced bacteriophage (crPhage) products targeting two key bacterial pathogens for the treatment of respiratory tract infection, and other related infections. Under this agreement, Janssen Pharmaceuticals, Inc. received license for CRISPR-Cas3-enhanced bacteriophage product from Locus Biosciences Inc. For this, Locus will receive US$ 20 million as initial payment which is expected to reach US$ 798 million from future commercialization and sales of the product.

Moreover, manufacturers are also collaborating with research institutes and hospitals in order to conduct clinical trials to evaluate phage therapy candidates, which is expected to further drive growth of the market. For instance, in May 2019, Intralytix, Inc., in collaboration with Mount Sinai Hospital, New York, initiated Phase 1/2 clinical trial to evaluate safety and efficacy of Ecoactive (Bacteriophage preparation) on intestinal adherent invasive e-coli in patients with inactive Crohn's disease.

Moreover, rising prevalence of drug resistant infections is expected to drive demand for bacteriophage therapy in the near future, which is expected to drive the market growth. For instance, according to the National Center for Biotechnology Information (NCBI), in 2015, the prevalence of antibiotic resistance in streptococcus pneumoniae was found to be high in children in Thailand. According to the NCBI, prevalence of multi-drug resistance S. pneumoniae (MDR-SP) was found to be 31.6%.

Bacteriophage Therapy Market - Regional Analysis

North America is expected to hold a dominant position in the global bacteriophage therapy market in 2018, owing to partnerships and acquisitions by players operating in the North America. For instance, in December 2018, Adaptive Phage Therapeutics (APT) entered into a collaboration agreement with the Paul Turner Lab at Yale University, to manufacture and supply therapeutic bacteriophage (phage) for use in clinical trials. Under the terms of agreement, APT will manufacture therapeutic phages as per the Food and Drug Administration (FDA) standards, and Good Manufacturing Practice (GMP) conditions. Similarly, in November 2016, ContraFect Corporation, a U.S. based company, entered into a collaborative research agreement with Rockefeller University (Rockefeller) to identify new lysin therapeutic candidates targeting Gram-negative bacteria.

Furthermore, increasing antimicrobial resistance among the populace is creating growth opportunities for manufacturers to expand their portfolio of phage therapy products which is expected to create a conducive environment for the growth of this market in the Asia Pacific region. For instance, in June 2019, the Vitalis Phage Therapy programme was launched in India. Vitalis Phage Therapy was developed by the Eliava Institute of Bacteriophages, Microbiology and Virology in Tbilisi, Georgia for patients from India. The Vitalis Phage Therapy programme provided an opportunity for the patients in India who want to undergo phage therapy at Eliava Phage Therapy Center (EPTC) in Georgia.

Key Players

Major players operating in the global bacteriophage therapy market are Armata Pharmaceuticals, Inc., Eliava Biopreparations Ltd., Pherecydes Pharma, Intralytix, Inc., Phagelux Inc., Nextbiotics, InnoPhage, Ltd, Locus Biosciences, Inc., TechnoPhage, Eligo Bioscience SA, Phagomed Biopharma GmbH., PhagePro, Inc., Adaptive Phage Therapeutics, Inc., EnBiotix, Inc., Intodeworld, Inc., BiomX Ltd., Phi Therapeutics, Fixed-phage Ltd., Micreos BV, and ContraFect Corporation.

Phage-based treatment is expected to emerge as a new treatment for managing persistent bacterial infections. Bacteriophage therapy has also played a significant role in research in the fields of molecular biology and biotechnology. These factors are widening the potential scope for drug discovery.

Market Dynamics

Increasing prevalence of drug resistant infections is expected to drive demand for bacteriophage therapy to overcome outbreak of infection. For instance, as per the Centers for Disease Control and Prevention (CDC), in February 2019, around 129 people from 32 U.S. states were infected with the outbreak strain of Salmonella Infantis. Moreover, the CDC also conducted antibiotic resistance testing on Salmonella bacteria isolated from infected patients. The outcomes of the tests showed that the outbreak strain was resistant to multiple antibiotics.

Increasing research and development of products is expected to propel the market growth. For instance, in September 2019, Armata Pharamceutical Inc. developed a new synthetic phage candidate targeting pathogen Pseudomonas aeruginosa for treatment of serious respiratory infections, with an emphasis on cystic fibrosis patients.

Moreover, rising collaboration and acquisition strategies by market players are expected to drive growth of the bacteriophage therapy market over the forecast period. For instance, in March 2018, AmpliPhi Biosciences Corporation (Armata Pharamceutical Inc.) collaborated with Australia-based Western Sydney Local Health District and the Westmead Institute for Medical Research, to expand access (indication) for its investigational bacteriophage candidates AB-SA01 and AB-PA01.

Key features of the study:

  • This report provides in-depth analysis of the bacteriophage therapy market
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global bacteriophage therapy market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as part of this study include Armata Pharmaceuticals, Inc., Eliava Biopreparations Ltd., Pherecydes Pharma, Intralytix, Inc., Phagelux Inc., Nextbiotics, InnoPhage, Ltd, Locus Biosciences, Inc., TechnoPhage, Eligo Bioscience SA, Phagomed Biopharma GmbH., PhagePro, Inc., Adaptive Phage Therapeutics, Inc., EnBiotix, Inc., Intodeworld, Inc., BiomX Ltd., Phi Therapeutics, Fixed-phage Ltd., Micreos BV, and ContraFect Corporation
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, technology upgradation, market expansion, and marketing tactics
  • The global bacteriophage therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the bacteriophage therapy market

Detailed Segmentation:

  • Global Bacteriophage Therapy Market, By Targeted Bacteria:
    • Escherichia coli
    • Staphylococcus
    • Streptococcus
    • Pseudomonas
    • Salmonella
    • Others
  • Global Bacteriophage Therapy Market, By Route of Administration:
    • Oral
    • Topical
    • Parenteral
  • Global Bacteriophage Therapy Market, By Region:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Company Profiles
    • Armata Pharmaceuticals, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Eliava Biopreparations Ltd.
    • Pherecydes Pharma
    • Intralytix, Inc.
    • Phagelux Inc.
    • Nextbiotics
    • InnoPhage, Ltd
    • Locus Biosciences, Inc.
    • TechnoPhage
    • Eligo Bioscience SA
    • Phagomed Biopharma GmbH.
    • PhagePro, Inc.
    • Adaptive Phage Therapeutics, Inc.
    • EnBiotix, Inc.
    • Intodeworld, Inc.
    • BiomX Ltd.
    • Phi Therapeutics
    • Fixed-phage Ltd.
    • Micreos BV
    • ContraFect Corporation

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Targeted Bacteria
      • Market Snippet, By Route of Administration
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Regulatory Scenario
    • PEST Analysis
    • PORTER’s Analysis
    • Recent Product Launch
    • Pipeline Analysis
    • Merger and Acquisition Scenario
  4. Global Bacteriophage Therapy Market, By Targeted Bacteria
    • Introduction
      • Escherichia coli
      • Staphylococcus
      • Streptococcus
      • Pseudomonas
      • Salmonella
      • Others
  5. Global Bacteriophage Therapy Market, By Route of Administration
    • Introduction
      • Oral
      • Topical
      • Parenteral
  6. Global Bacteriophage Therapy Market, By Region
    • Introduction
      • North America
      • Latin America
      • Europe
      • Asia Pacific
      • Middle East
      • Africa
  7. Competitive Landscape
    • Heat Map Analysis
      • Armata Pharmaceuticals, Inc.*
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Eliava Biopreparations Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pherecydes Pharma
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Intralytix, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Phagelux Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Nextbiotics
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • InnoPhage, Ltd
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Locus Biosciences, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • TechnoPhage
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Eligo Bioscience SA
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Phagomed Biopharma GmbH.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • PhagePro, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Adaptive Phage Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • EnBiotix, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Intodeworld, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • BiomX Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Phi Therapeutics
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Fixed-phage Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Micreos BV
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • ContraFect Corporation
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  8. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 146 pages on "Bacteriophage Therapy Market - Global forecast to 2027”.

Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner